Reference : Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postm...
Scientific journals : Article
Business & economic sciences : Special economic topics (health, labor, transportation…)
Human health sciences : Rheumatology
http://hdl.handle.net/2268/40396
Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.
English
Hiligsmann, Mickaël mailto [Université de Liège - ULg > HEC-Ecole de gestion de l'ULg : UER > Economie industrielle >]
Bruyère, Olivier mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique >]
Reginster, Jean-Yves mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique >]
2010
Bone
46
2
440-6
Yes (verified by ORBi)
International
8756-3282
1873-2763
[en] cost-effectiveness ; osteoporosis ; postmenopausal women ; risedronate ; strontium ranelate
[en] OBJECTIVE: To estimate the cost-effectiveness of strontium ranelate in the treatment of postmenopausal osteoporotic women aged over 75 years. MATERIALS AND METHODS: A validated Markov microsimulation model with a Belgian payer's perspective estimated the cost per quality-adjusted life-year (QALY) of a 3-year strontium ranelate treatment compared with no treatment and with the bisphosphonate risedronate. Data on the effect of both treatments on fracture risk were taken from the Cochrane Database of Systematic Reviews. Analyses were performed for postmenopausal women aged 75 and 80 years, either with a diagnosis of osteoporosis (i.e. bone mineral density T-score </=-2.5 SD) or with prevalent vertebral fractures (PVF). Parameter uncertainty was evaluated using both one-way and probabilistic sensitivity analyses. RESULTS: Strontium ranelate was dominant (i.e. more effective and less costly) versus risedronate for women with osteoporosis aged over 75 years and for women with PVF aged 80 years. The cost per QALY gained of strontium ranelate compared with risedronate at 75 years of age was euro11,435 for women with PVF. When compared with no treatment, the costs per QALY gained of strontium ranelate were euro15,588 and euro7,708 at 75 and 80 years of age for women with osteoporosis; the equivalent values were euro16,518 and euro6,015 for women with PVF. Probabilistic sensitivity analyses showed that strontium ranelate was generally more cost-effective than risedronate, in the range of 60% in all cases. CONCLUSION: The results of this study suggest that strontium ranelate is a cost-effective strategy, in a Belgian setting, for the treatment of postmenopausal osteoporotic women aged over 75 years.
Researchers ; Professionals
http://hdl.handle.net/2268/40396
10.1016/j.bone.2009.08.052

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Bone2_Hiligsmann.pdfPublisher postprint346.17 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.